<DOC>
	<DOCNO>NCT00330889</DOCNO>
	<brief_summary>This study assess Pharmacokinetic ( PK ) Pharmacodynamic ( PD ) effect Prednisolone Rheumatoid Arthritis ( RA ) patient .</brief_summary>
	<brief_title>Effects Of Prednisolone On Rheumatoid Arthritis Patients</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Inclusion criterion : Meet ACR criterion diagnosis rheumatoid arthritis . Required treatment Prednisolone . Currently nonsteroidal antiinflammatory agent ( NSAID ) . Willing stay current dose NSAID two week study . Exclusion criterion : Major health issue osteoporosis , diabetes , heart failure , heart attack , kidney failure , acute infection .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>